Cancer of the Colon and Rectum – Cancer Stat Facts
Colorectal Cancer statistics
Related Articles
Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma
Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.
2024 Orphan Drugs: PDUFA Dates and FDA Approvals
Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory…
Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
SEER*Explorer Application
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number…
Expert Urges Researchers to Challenge Dogma & Forge Novel… : Oncology Times
An abstract is unavailable.
BET Inhibitor Shows Encouraging Safety and Tolerability in Myelofibrosis | Blood Cancers Today
The phase 1 study found that INCB057643, as monotherapy or in combination with ruxolitinib, was generally well tolerated in patients with relapsed or refractory MF.
OCE Oncology News
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
Updates in CLL Treatment: 5-Year Off-Treatment Analyses From the CLL14 and MURANO Trials
This video presents the 5-year off-treatment analyses from the CLL14 and MURANO studies.
